We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation Treatment

This study has suspended participant recruitment.
(Study suspended by decision strategically.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01244659
First Posted: November 19, 2010
Last Update Posted: March 4, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
EMS
  Purpose
Comparison of safety and efficacy of immunosuppressive regiments using tacrolimus from EMS and Prograf® in post renal transplanted patients.

Condition Intervention Phase
Renal Transplant Drug: Tacrolimus from EMS Drug: Prograf Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Randomized Non-inferiority Study to Compare Safety and Efficacy of Immunosuppressive Regiments Using Tacrolimus From EMS and Prograf® in Post Renal Transplanted Patients

Resource links provided by NLM:


Further study details as provided by EMS:

Primary Outcome Measures:
  • Efficacy [ Time Frame: day 1 to day 180 ]
    Incidence of biopsy confirmed acute rejection


Secondary Outcome Measures:
  • Safety [ Time Frame: day 1 to day 180 ]
    1. Patient and graft survival
    2. Renal function control by Estimated Glomerular Filtration Rate
    3. Safety, including incidence of post-transplant infection, malignances, diabetes mellitus, hepatotoxicity, blood pressure control and lipidic profile evaluation.


Estimated Enrollment: 60
Study Start Date: May 2014
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tacrolimus from EMS
Group 1: Tacrolimus from EMS + Myfortic® + Steroids
Drug: Tacrolimus from EMS
Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
Active Comparator: Prograf
Group 2: Prograf® + Myfortic® + Steroids
Drug: Prograf
Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age > 18 year old
  • Patient is receiving kidney from live or death donor
  • Kidney donor younger than 65 years old
  • PRA ≤ 30%
  • Negative pregnancy test for women
  • Patient agreement to practice birth control
  • Patient has been fully informed and has given written informed consent

Exclusion Criteria:

  • HLA identical
  • Patient multi-organ transplant recipient
  • Any pathology or past medical condition that can interfere with this protocol
  • Allergy or intolerance of any study medication
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01244659


Locations
Brazil
Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, RS, Brazil, 90020090
Sponsors and Collaborators
EMS
Investigators
Study Director: Felipe Pinho, MD EMS
  More Information

Responsible Party: EMS
ClinicalTrials.gov Identifier: NCT01244659     History of Changes
Other Study ID Numbers: TACEMS0410
First Submitted: November 18, 2010
First Posted: November 19, 2010
Last Update Posted: March 4, 2013
Last Verified: March 2013

Keywords provided by EMS:
Tacrolimus
Immunosuppressive Agents
Kidney transplantation

Additional relevant MeSH terms:
Tacrolimus
Immunosuppressive Agents
Mycophenolic Acid
Methylprednisolone
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Protective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents